Hepatitis C has become a major clinical and public health problem worldwide. Accordingly, pharmaceutical research companies are making efforts to develop new synthetic medicinal compounds along with biologics, drug combinations and new dosage forms. The approval of two new synthetic medicinal compounds in late 2013 namely sofosbuvir and simeprevir by the U.S. Food and Drug Administration (U.S. FDA) for the treatment of hepatitis C is the result of the efforts made by these pharmaceutical research companies. The U.S. FDA approved synthetic medicinal compounds have opened the door for the oral regimens as the future standard of treatment for hepatitis C. This review article provides preliminary information about recently approved synthetic medicinal compounds as well as some important synthetic medicinal compounds in the pipeline for the treatment of hepatitis C.
Select your language of interest to view the total content in your interested language